"The total capital will enable a significant increase in Cynata’s clinical development pipeline, opening multiple promising new opportunities for the Company’s unique Cymerus™ technology. With a growing interest in induced pluripotent stem cell (iPSC)-driven manufacturing strategies for cell therapy products Cynata remains the global leader with the most advanced product portfolio and strong clinical trial data."
CYP Price at posting:
77.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)